On August 20, 2018, the U.S. Department of Health and Human Services (HHS) released an analysis of the accomplishments that the Trump administration has achieved in the first 100 days since the release of the President’s American Patients First Blueprint to lower prescription drug prices. The HHS Report on 100 Days of Action on the American Patient First Blueprint provides some interesting insight into the Trump administration’s progress on delivering on their promise of lower drug prices. While there is a lot that needs deciphering, HHS made two very significant claims in this report. They assert that over the first 100 days since the Blueprint's release there have been significantly less brand-drug price increases, and significantly more generic and brand price decreases. After some careful number-crunching and analysis, we can now tell you where we believe the administration seems to be making headway and where things still seem incomplete. More importantly, we hope we can provide some better clarity into whether or not any current actions have directly impacted lower drug costs. Check out our newest research that shows what really happened to drug prices in the first 100 days since the release of the White House blueprint.

Read More